Kibow Biotech/Pharmaceuticals Company, 24, from Pennsylvania, USA, supports World Kidney Day 2022 as part of its mission “Kidney Health for All”.

NEWTOWN SQUARE, Pennsylvania., March 10, 2022 /PRNewswire/ — Kibow Biotech is pleased to announce that it is joining and celebrating World Kidney Day (WKD) on March 10, 2022. Its theme is Kidney health for all, with an effective social media campaign and financial support for its activities. This year’s campaign aims to bridge the knowledge gap among stakeholders in order to improve kidney disease care at all levels of patient quality of life. Moreover, Kibow Biotech will continue to support the various awareness campaigns, educational and preventive health programs among key community stakeholders, health workers and public health decision makers to reduce the enormous challenges with more than hundred billion dollars in the management of kidney disease. Kidney disease is now at the forefront of awareness and a burden on healthcare spending (News: IRC takes center stage with launch of Kidney Care Choices model).

world kidney day

Chronic kidney disease (CKD) affects approximately 10% of the adult population worldwide and 15% of the US population. It is associated with high health costs and mortality. Additionally, CKD is a global public health threat and is expected to be the 5and leading cause of death by 2040. Therefore, raising awareness and closing the knowledge gap is a weapon we all need to fight kidney disease and rising mortality.

In this regard, the team and partners of Kibow Biotech have, for more than 24 years, been involved in R&D to provide solutions and support people around the world struggling with kidney failure. Kibow has been at the forefront of helping CKD patients and families navigate their kidney health through educational materials and ongoing research efforts in developing new dietary supplement formulations that provide additional health benefits and improve consumers’ quality of life. Kibow’s focus on kidney health has been delaying dialysis in patients with CKD stage IV with proprietary proprietary formulation of Renadyl™ probiotic dietary supplements marketed since April 2010 ( Kibow’s platform technology is known as “Enteric/intestinal dialysis”, which metabolizes various uremic toxins that diffuse blood circulating in the intestine (Platform Technology Video).

As part of Kibow’s scientific R&D and drug development programs, a separate pharmaceutical division was launched in 2019 to transition probiotic supplements for kidney health into a drug-grade Live Biotherapeutics (LBP) category. The Company has obtained an FDA-approved IND for US-APR2020 for Phase 2b Clinical trial to evaluate safety and efficacy in 630 subjects with stage IV CKD. This first large-scale phase 2b double-blind randomized controlled clinical trial actively recruiting subjects at 20 US sites for October 2021 and hopes to complete the study before the end of this year (NCT04913272). The Company is also exploring its use and clinical benefits of improved pro/prebiotic formulations for pediatric subjects with CKD who have limited current treatment options.

Additionally, the Company’s clinical development program is also in the process of submitting an IND application to the US FDA and obtaining IND approval to evaluate the CKD Stage 4 formulation, US-APR 2020, with an additional specific probiotic strain selected for its ability to reduce catheter and hospital infection in patients undergoing routine hemodialysis three times per week and four hours per session or less. This study is about to assess the potential for reducing the duration and/or frequency of dialysis with improved quality of life and better outcomes.

Since 1997, Kibow Biotech, Inc has continuously researched, developed and marketed probiotic dietary supplements that comply with US FDA and FTC regulations. The company has fulfilled this primary mission by providing readily available, accessible and affordable formulations to support kidney health and other clinical applications by marketing their products in the United States and various other countries around the world, based on government requirements. regulations of each country. In addition, the Company’s efforts to move to LBP classification may be subject to a therapeutic claim and thus benefit from medical reimbursement – both by Medicare and by private health insurance companies. Therefore, our company’s quarter century of effort is to validate, scientifically support and align our philosophy with the Kidney Care Choices model recently launched by the Centers for Medicare and Medicaid Innovation (CMMI) for Stages 4 and 5 of the IRC. Kibow Biotech and Kibow Pharmaceutical’s clinical development programs aim to raise awareness of kidney health, provide treatment choices and improve the quality of life for patients with CKD at all stages worldwide.

For more information, contact:
Dr. Emmanuel Anteyi, MD, MBA, MSHS, FRCP (Lon)
Medical/Clinical Director
Phone: (610) 353-5130
Email: [email protected]

Related links

On Kibow Biotech, Inc. Founded on October 1, 1997 in Philadelphia, Kibow Biotech specializes in the research, development and marketing of probiotic dietary supplements that comply with US FDA and FTC regulations. The company’s primary mission is to provide affordable, readily available, and easy-to-administer nutritional supplements to support kidney health and other healthcare applications. In accordance with government rules and regulatory authorities in each country, the Company’s lead product, Renadyl™, is marketed in the United States and Canada, as well as in several other countries, as a dietary supplement for the kidneys. The company’s extensive scientific (R&D) and clinical data, including three pilot/observational human clinical trials, have been published in peer-reviewed scientific/medical journals ( rd/).

On Kibow Pharmaceuticals, LLC. Kibow Pharmaceuticals, LLC., (a Delaware limited liability company), is a wholly owned subsidiary of Kibow Biotech, Inc. The pharmaceutical division was established in 2019 primarily for clinical development to evaluate the safety and effectiveness of living biotherapeutic pharmaceuticals (LBPs).

Forward-looking statements; This press release contains forward-looking statements that reflect management’s current beliefs regarding future events. These statements include the development and transition status of the currently marketed kidney health dietary supplement to its wider recognition, acceptance, and commercial potential as a “Living Biotherapeutic (LPB)” in the United States and throughout other countries. For now, Kibow® the products are not medicines and cannot be considered as treatment or therapy. The Renadyl™ dietary supplement formulation is not intended to cure, prevent or ameliorate any disease. Due to several factors, clinical data results offered as low back pain results may differ materially from the above forward-looking statements. These include, but are not limited to, the possibility that Renadyl™ may not reduce uremic toxin levels in every individual due to differences that exist between individuals that cannot be controlled, such as genetic factors. and lifestyle, as well as environmental factors which include proper storage of the product and conditions for transporting the product through the trade chain. Other factors that could cause or contribute to differences in actual results include, but are not limited to: whether the Company or any of its associates will be able to meet regulatory requirements for human drugs using Company technologies; whether the Company’s cash resources will be sufficient to fund the operations as planned; dependence on key employees, particularly senior management; the uncertainty of the Company’s future access to capital; the risk that the Company may not be able to secure or maintain relationships with employees; and the Company’s dependence on intellectual property. The Company expressly disclaims any intention or obligation to update these forward-looking statements, except as required by law.



View original content to download multimedia: -on -sa-mission-kidney-health-for-all-301500129.html

SOURCE Kibow Biotech, Inc.

Comments are closed.